Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
| HCPC | S0176 |
| Short Description | Hydroxyurea 500 mg |
| Long Description | Hydroxyurea, oral, 500 mg |
| Pricing indicator | 00 |
| Coverage code | I |
| ASC payment group code | |
| BETOS2 code | Z2 |
| Action code | N |
| Type of service | 9 |
| Effective date | 2002-01-01 |
| Date Added | 2002-01-01 |
Drug Details
-
Hydroxyurea (Hydrea) is used alone or with other medications or radiation therapy to treat a certain type of chronic myelogenous leukemia (CML; a type of cancer of the white blood cells) and certain types of head and neck cancer (including cancer of the mouth, cheek, tongue, throat, tonsils, and sinuses). Hydroxyurea (Droxia, Siklos) is used to reduce the frequency of painful crises and reduce the need for blood transfusions in adults and children 2 years of age and older with sickle cell anemia (an inherited blood disorder in which the red blood cells are abnormally shaped [shaped like a sickle] and cannot bring enough oxygen to all parts of the body). Hydroxyurea is in a class of medications called antimetabolites. Hydroxyurea treats cancer by slowing or stopping the growth of cancer cells in your body. Hydroxyurea treats sickle cell anemia by helping to prevent formation of sickle-shaped red blood cells.